Industry Picks Holes In UK Plans For Post-Brexit Drug Regulation

Plans for a post-Brexit standalone regulatory system have drawn a mixed response from UK pharmaceutical industry bodies, which are worried about aspects of proposals on future drug approval routes, orphan and pediatric drug incentive schemes, and the “grandfathering” of existing EU marketing authorizations. They are also calling for financial compensation should the UK not be part of Europe's the new drug verification system.